IMPAACT at CROI 2026

Long-acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results

Gaur A, Baltrusaitis K, Capparelli E, Lowenthal E, Marzinke M, Crauwels H, Cheung A, Townley E, Moye J, Whitton M, Masheto G, Mathiba SR, Heckman B, Bolton Moore C

Viral Control among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies

Ajibola G, Sakoi M, Batlang O, Nelson BS, Pretorius Holme M, Kasongo M, Powis KM, Moyo S, Hughes MD, Yin DE, Jean-Philippe P, Nachman S, Lockman S, Lichterfeld M, Shapiro RL

Viremia Accelerates VRC01 Clearance in Infants Living with HIV-1: Insights from IMPAACT 2008

Gan JC, McFarland EJ, Tierney C, Khaitan A, Persaud D, Cotton M, Yin D, Moye J, Spiegel H, Mallewa M, Perlowski C, Mvalo T, Stotz C, Capparelli E, for the IMPAACT 2008 Study Team

Higher Infant Mortality with Efavirenz-based vs. Dolutegravir-based ART in Pregnancy: IMPAACT 2010

Korutaro V, Ziemba L, Brummel S, Coletti A, Jean-Philippe PJ, Chakhtoura N, Johnston B, Stranix-Chibanda L, Fairlie L, Shapiro R, Wabwire D, Nahirya Ntege P, Chinula L, Lockman S, on behalf of the IMPAACT 2010/VESTED team

In utero exposure of dolutegravir and efavirenz assessed via hair levels in IMPAACT 2010 trial 

Pintye J, Okochi H, Chawana T, João E, Hanley S, Aurpibul L, Stotz C, McCarthy K, Jean-Philippe P, Chakhtoura N, Brummel S, Momper J, Chinula L, Lockman S, Gandhi M

Primary Findings of IMPAACT 2016: a RCT of a Youth-Led Mental Health Intervention for Youth with HIV  (View themed discussion here)

Dow D, Libous J, Davies Smith E, Dirschberger R, Varechtchouk O, Lee S, Vhembo T, Stranix-Chibanda L, Nematadzira T, Ponatshego PL, Maliwichi L, Mvalo T, Buckley J, Montañez N, Donenberg G

Implementation Outcomes of IMPAACT 2016: A Peer-Led Mental Health Intervention for Youth with HIV

Donenberg G, George K, Montañez N, Davies Smith E, Brouwers E, Mandima P, Bere T, Maonera S, Masheto G, Gadama D, Mvalo T, Gavin L, Mwenda W, Townley E, Dow D

Safety and pharmacokinetics of long-acting cabotegravir and rilpivirine in children 10 to <40 kg

Archary M, Pinto J, Caparelli E, Acosta E, Cheung A, Crauwels H, Townley E, Moye J, Giganti M, Scheckter R, Heckman B, Hofer C, Dhar M, Mathiba SR, for the CRAYON/IMPAACT 2036 Study Team

Safety and Pharmacokinetics of VRC07-523LS, PGDM1400LS, and PGT.121.414.LS in combination among children in Botswana

Capparelli EV, Ajibola G, Nelson BS, Pretorius Holme M, Powis KM, Seaton KE, Hughes MD, Yin D, Jean-Philippe P, Lockman S, Makhema J, Moyo S, Kuritzkes DR, Lichterfeld M, Shapiro RL

Susceptibility Patterns for VRC07-523LS, PGDM1400LS, and PGT121.414.LS among Children in Botswana

Moraka-Mankge NO, Ajibola G,Lancien M, Reeves JD, Persyn T,Pretorius Holme M, Nelson BS, Hughes MD, Yin DE, Jean-Philippe P, Powis KM, Moyo S, Nachman S, Kuritzkes DR, Lichterfeld M, Shapiro RL

Levels of Inflammation and Immune Activation in Infants who are HIV-Exposed but Uninfected Throughout the First 12 Months of Life

Roseto I, Silveria L, Curtis K, Canniff J, Weinberg A, Smith C

Efavirenz Pharmacokinetics in Pregnancy and Postpartum With and Without First-line TB Drugs

Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Shapiro DE, Cressey TR, Theron GB, Cotton MF, Browning R, DeYampert T, Capparelli EV, Stek AM, Mirochnick M, Best BM, Eke AC, on behalf of the IMPAACT P1026s Protocol Team

Cytokines in pregnant and postpartum women with HIV and latent TB: results from IMPAACT P1078

Wei Z, Morrow M, MaWhinney S, Gupta A, Weinberg A, Montepiedra G, Violari A, Theron G, Ponatshego P, Masheto G, Hesseling A, Anderson PL, Brooks KM, on behalf of the IMPAACT P1078 Study Team

Anti-HIV monoclonal antibodies in oral secretions after SC administration to newborns exposed to HIV

McFarland EJ, Capparelli EV, Giganti MJ, Seaton K, Brackett C, Perlowski C, Yin DE, Spiegel H, Moye J,  Majji S, Harding PA, Koup RA, Tomaras G, Cunningham CK, for the IMPAACT P1112 team

Very Early ART +/- VRC01 for In Utero HIV-1: Virologic Outcomes at 2 Years of Age in IMPAACT P1115

Jao J, Abbott M, Tierney C, Vhembo T, Nematadzira T, Stranix-Chabanda L, Kosegei J, Coletti A, Wojcinski S, Jennings C, Yin D, Moye J, Persaud D, Chadwick EG, for the IMPAACT P1115 study team

Neutralizing antibody, VRC01, PK and safety among infants initiating very early ART in IMPAACT P1115

McFarland EJ, Capparelli EV, Abbott M, Tierney C, Perlowski C, Bwakura-Dangarembizi N, Mhembere T, Mvula H, Jean-Philippe P, Moye J, Costello D, Wojcinski S, Lin BC, Chadwick E, for the P1115 team

Harnessing proviruses to define bNAb sensitivity in infants with in utero HIV-1 (IMPAACT P1115)

Bekka S, Dhummakupt A, O’Dell S, Tourtellott E, Nelson BS, Naidoo KL, Malunda B, Bwakura-Dangarembizi M, Costello D, Yin DE, Majji S, Rawi R,  Chadwick EG, Doria-Rose N, Persaud D

TORCH Infections as Risk Factor for Adverse Birth Outcomes Among HIV-Exposed Neonates in Uganda

Atuhaire P, Giganti MJ, McMorrow F, Owor M, Musoke P, Fowler MG, for the PROMISE 1077BF team